Despite his tax woes, Shkreli is offering $10 million to Kanye West for sole possession of the singer's new album.» Read More
CNBC correspondent Julia Chatterley reports on Novartis' 4th quarter net income of $2.7 billion, which was below forecasts.
Xavier Rolet, CEO of the London Stock Exchange, talks about the success pharma and health care companies have had raising capital in the U.K.
CNBC's Meg Tirrell highlights the increasingly popular political stance against increasing drug prices.
Donald Trump reportedly supports Medicare negotiating the price of prescription drugs, claiming it would save $300 billion annually.
CNBC takes a look at Zika, a mosquito-borne virus spreading fast across the Americas and the Caribbean for which there is no cure.
Ex-CEO Shkreli will talk to his followers on social media, but not to Congress, which is asking for testimony on drug prices. The NYT reports.
The Nasdaq biotech index traded lower following a tweet from Hillary Clinton disparaging higher drug prices, reports CNBC's Meg Tirrell.
Former Medtronic CEO Bill George matches up industry competitors and offers up this scorecard of CEOs with solid strategies that are worth betting on.
Valeant's ailing CEO, Michael Pearson, said he was on the road to recovery but was uncertain about when he would return from medical leave.
Cigna said the suspension does not affect members currently enrolled in these plans.
Valeant's interim chairman and CEO say the pharma giant is making changes in "a number of areas" to "correct our missteps."
The controversial former drug exec, facing fraud charges, is also objecting to being a called a "pharma bro."
Peder Holk Nielsen, CEO of Novozymes, explains why the company has downgraded its outlook for sales growth.
Health care CEOs discuss the three traits they believe define what makes a good leader.
Health care CEOs discuss what they believe defines success in the pharmaceutical and biotech industries.
Len Yaffe, Stoc Doc Partners, weighs in on biotech's best bets.
JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.
CNBC's Bertha Coombs highlights the big Nasdaq laggards as biotech concerns weigh.
After selling off more than 5 percent, RBC Capital Markets' Michael Yee discusses the state of biotech.
David Agus, "The Lucky Years" author, discusses how innovative health technology could help prevent some diseases and actually increase life expectancy.
Get the best of CNBC in your inbox